Lead program Elafibranor is PPAR alpha/delta agonist in Ph 3 for NASH with data expected by 1Q20. Upcoming 2020 milestones include: NASH Fibrosis (NTZ) Ph 2 data readout, NASH combination (elafibranor + GLP-1/SGLT-2) Ph 2 POC trial initiation, PBC (elafibranor) Ph 3 trial initiation and NIS4 (IVD/biomarker) clinical commercialization initiation in partnership with Labcorp/Covance.
US - New England
Anti-inflammatory, Metabolic Disorders
100MM - 500MM
245, First Street, 18th Floor
Cambridge, MA 02142
Top 10 Holders of Genfit SA
Top 10 Holders of Genfit SA Sponsored ADR
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by